Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease

Osteoarthritis (OA) is the most common joint disease globally, and its incidence increases with age – up to 80–90% in people over 60 years. There is a high comorbidity between OA and cardiovascular diseases (CVD), such as arterial hypertension (AH), atherosclerosis, and coronary heart disease (CHD). The main objectives of OA therapy include pain reduction, cartilage matrix preservation, safe profile in patients with comorbid diseases, minimal adverse effects. In addition, the drug should be comparable in analgesic effects with nonsteroidal anti-inflammatory drugs (NSAIDs). Such drugs include structural-modifying agents – symptomatic slow-acting drugs for osteoarthritis (SYSADOA), one of which is chondroitin sulfate (CS). According to the 2019–2020 International and Russian guidelines, only pharmaceutical-grade CS is recommended for use. The high efficacy of intramuscular administration of CS in patients with OA, lower back pain, and comorbid diseases (AH, CHD, atherosclerosis) has been proven. CS is prescribed for a long treatment course – up to two months.

1. Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21. doi: 10.14412/1996-7012-2019-2-9-21 (In Russ.).

2. Portyannikova OO, Tsvinger SM, Govorin AV, et al. Analysis of the prevalence and risk factors of osteoarthritis in a population. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):105-11. doi: 10.14412/1996-7012-2019-2-105-111 (In Russ.).

3. Arden N, Nevit MC. Osteoarthritis: Epidemiology. Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25. doi: 10.1016/j.berh.2005.09.007

4. Yoshimura N, Nakamura K. Epidemiology of locomotive organ disorders and symptoms: an estimation using the population-based cohorts in Japan. Clin Rev Bone Miner Metab. 2016;14:68-73. doi: 10.1007/s12018-016-9211- 7. Epub 2016 Jun 7.

5. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Al'manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018;46(1):32-9. doi: 10.18786/2072-0505-2018-46-1-32-39 (In Russ.).

6. Balabanova RM, Dubinina TV, Demina AB, et al. The incidence of musculoskeletal diseases in the Russian Federation over 2015–2016. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(1):15-21. doi: 10.14412/1995-4484-2018-15-21 (In Russ.).

7. Sharapova EP, Kashevarova NG, Naskina EA, et al. Evaluation of the efficacy, tolerability and safety of chondrogard in patients with osteoarthrosis of the knee and comorbidity. Farmateka = Pharmateca. 2017;7(340):46-51 (In Russ.).

8. Yoshimura N, Muraki S, Nakamura K, et al. Epidemiology of the locomotive syndrome: the research on osteoarthritis / osteoporosis against disability study 2005–2015. Mod Rheumatol. 2017 Jan;27(1):1-7. doi: 10.1080/14397595.2016.1226471

9. Dydykina IS, Nurbaieva KS, Kovalenko PS, et al. From knowing the mechanism of action to choosing a method for the prevention and treatment of osteoarthritis. RMJ. 2020;(7):14-8 (In Russ.).

10. Wang X, Yao S, Wang M, et al. Multimorbidity among two million adults in China. Int J Environ Res Public Health. 2020 May 13;17(10):3395. doi: 10.3390/ijerph17103395

11. Blümel JE, Carrillo-Larco RM, Vallejo MS, et al. Multimorbidity in a cohort of middle-aged women: risk factors and disease clustering. Maturitas. 2020 Jul;137:45-9. doi: 10.1016/j.maturitas.2020.04.016. Epub 2020 May 4.

12. Lee KM, Chung CY, Sung KH, et al. Risk factors for osteoarthritis and contributing factors to current arthritic pain in South Korean older adults. Yonsei Med J. 2015 Jan;56(1):124- 31. doi: 10.3349/ymj.2015.56.1.124

13. Swain S, Sarmanova A, Coupland C, et al. Comorbidities in osteoarthritis: a systematic review and meta-analysis of observational studies. Arthritis Care Res. 2020 Jul;72(7):991-1000. doi: 10.1002/acr.24008. Epub 2020 Jun 7.

14. Xie Y, Zhou W, Zhong Z, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021 Feb;40(2):711-24. doi: 10.1007/s10067-020-05216-y. Epub 2020 Jul 23.

15. Wang H, Bai J, He B, et al. Osteoarthritis and the risk of cardiovascular disease: a meta-analysis of observational studies. Sci Rep. 2016 Dec 22;6:39672. oi: 10.1038/srep39672

16. Veronese N, Stubbs B, Solmi M, et al. Osteoarthritis increases the risk of cardiovascular disease: data from the Osteoarthritis Initiative. J Nutr Health Aging. 2018;22(3):371- 6. doi: 10.1007/s12603-017-0941-0

17. Veronese N, Stubbs B, Solmi M, et al. Knee osteoarthritis and risk of hypertension: a longitudinal cohort study. Rejuvenation Res. 2018 Feb;21(1):15-21. doi: 10.1089/rej.2017.1917. Epub 2017 Nov 20.

18. Lo GH, McAlindon TE, Katz JN, et al. Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clin Rheumatol. 2017 Sep;36(9):2121-8. doi: 10.1007/s10067-017-3656-z. Epub 2017 Jun 1.

19. Franceschi C, Garagnani P, Vitale G, et al. Inflammaging and «Garbaging». Trends Endocrinol Metab. 2017 Mar;28(3):199-212. doi: 10.1016/j.tem.2016.09.005. Epub 2016 Oct 24.

20. Minciullo PL, Catalano A, Mandraffino G, et al. Inflammaging and antiinflammaging: the role of cytokines in extreme longevity. Arch Immunol Ther Exp (Warsz). 2016 Apr;64(2):111-26. doi: 10.1007/s00005-015-0377-3. Epub 2015 Dec 12.

21. Loeser RF, Yammani RR, Carlson CS, et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum. 2005 Aug;52(8):2376-85. doi: 10.1002/art.21199

22. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur Respir J. 2015 Mar;45(3):790-806. doi: 10.1183/09031936.00229714. Epub 2015 Jan 22.

23. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P, et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis. 2016;245:82-7. doi: 10.1016/j.atherosclerosis.2015.12.016

24. Lila AM, Torshin IYu, Gromova OA. Is it worthwhile rethinking the positive experience of the last 50 years of using chondroitin sulfates against atherosclerosis? Sovremennaya farmakoekonomika i farmakoepidemiologiya = Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(2):184-91. doi: 10.17749/2070-4909/farmakoekonomika.2020.043 (In Russ.).

25. Parcernyak AS, Khalimov YuSh. Chronic inflammation and premature aging – two parallel processes in polymorbid cardiovascular pathology. Vestnik Rossiyskoy voyenno-meditsinskoy akademii = Bulletin of the Russian Military medical Academy. 2019;3(67):78-82 (In Russ.).

26. Shavlovskaya OA, Zolotovskaya IA, Prokofyeva YuA. A new look at back pain treatment in light of the latest ESCEO guidelines. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):90-5. doi: 10.14412/2074-2711-2020-6-90-95 (In Russ.).

27. Klinicheskie rekomendacii MZ RF. «Hronicheskaya bol’ u pacientov pozhilogo i starcheskogo vozrasta». 2020 [Clinical guidelines of the Ministry of Health of the Russian Federation «Chronic pain in elderly and senile patients.» 2020]. Available from: https://cr.rosminzdrav.ru/#!/recomend/1033 (accessed 30.04.2021) (In Russ.).

28. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008

29. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62. doi: 10.1002/acr.24131

30. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99. doi: 10.1136/annrheumdis2019-216655

31. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011

32. Identification number of the CI protocol of the Ministry of Health of the Russian Federation: KI/1216-1. Double-blind, placebo-controlled, randomized study of the efficacy and safety of Chondrogard, solution for intramuscular injection 100 mg/ml (ZAO PharmFirma Sotex, Russia) in patients with gonarthrosis. Available from: https://grls.rosminzdrav.ru/ (accessed 30.04.2021) (In Russ.).

33. Gromova OA, Torshin IYu, Zaychik BTs, et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(1):50-62. doi: 10.17749/2070-4909/farmakoekonomika.2021.083 (In Russ.).

34. Nigro J, Ballinger ML, Survase S, et al. New approaches to regulating the chondroitin/dermatan sulfate glycosaminoglycan component of the vascular extracellular matrix. Scient World J. 2005 Jul 12;5:515-20. doi: 10.1100/tsw.2005.69

35. Stabler TV, Montell E, Vergеs J, et al. Chondroitin sulfate inhibits monocyte chemoattractant protein-1 release from 3T3-L1 adipocytes: a new treatment opportunity for obesity-related inflammation? Biomarker Insights. 2017;12:1-4. doi: 10.1177/1177271917726964

36. Torshin IYu, Lila AM, Gromova OA, et al. Anticoagulant and antiplatelet effects of chondroitin sulfate. RMJ. 2020;(7):44-8 (In Russ.).

37. Herrero-Beaumont G, Marcos ME, Sanchez-Pernaute O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol. 2008;154(4):843-51. doi: 10.1038/bjp.2008.113

38. Gregori D, Giacovelli G, Minto C, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis. JAMA. 2018;320(24):2564-79. doi: 10.1001/jama.2018.19319

39. Torshin IYu, Lila AM, Naumov AV, et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):399-410. doi: 10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.).

40. Evstratova EF, Vasileva LV, Nikitin AV, et al. Differentiated approaches in the treatment of spondyloarthrosis, arc-chained joints, spinal column and osteoarthritis of the knee in patients with concomitant pathology of the digestive system. Tendentsii razvitiya nauki i obrazovaniya = Trends in the Development of Science and Education. 2019;47(5):42-7. doi: 10.18411/lj-02-2019-99 (In Russ.).

41. Zolotovskaya IA, Davydkin IL, Poverennova IE. Therapy of nonspecific lower back pain in patients with high cardiovascular risk. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8):18-23. doi: 10.17116/jnevro201911908118 (In Russ.).

42. Vasil'eva LV, Evstratova EF, Nikitin AV, et al. Differentiated approach to treatment of osteoarthrosis in cardiovascular pathology. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016;2(130):84-9. doi: 10.15829/1560-4071-2016-2-84-89 (In Russ.).

43. Sarvilina IV, Galustyan AN, Hadzhidis AK, et al. Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):255-66. doi: 10.17749/2070-4909.2019.12.4.255-266 (In Russ.).